预约演示
更新于：2025-04-19
Cefazolin Sodium
头孢唑林钠
更新于：2025-04-19
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1973-10-04), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H24N8NaO9S3 |
InChIKeyCQCPLXCVNXNUCK-HGUWTHONSA-N |
CAS号115850-11-8 |
关联
153
项与 头孢唑林钠 相关的临床试验NCT06920147
PRevention Of Trauma-related Infections Through an Embedded Clinical Trials (PROTECT) Network
NCT06567808
Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial
NCT06406114
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
100 项与 头孢唑林钠 相关的临床结果
登录后查看更多信息
100 项与 头孢唑林钠 相关的转化医学
登录后查看更多信息
100 项与 头孢唑林钠 相关的专利（医药）
登录后查看更多信息
18,221
项与 头孢唑林钠 相关的文献（医药）2025-07-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
A case of pyogenic vertebral osteomyelitis and psoas abscess caused by Haemophilus influenzae: Diagnostic value of 16S ribosomal RNA gene analysis in a culture-negative case
Article
作者: Oshiro, Yusuke ; Toma, Kenya ; Shinzato, Takashi ; Ohkusu, Kiyofumi ; Ishiki, Haruka
Haemophilus influenzae is a rare cause of pyogenic osteomyelitis, with only eleven reported adult cases. We present a case of H. influenzae vertebral osteomyelitis and psoas abscess in a 48-year-old woman who had received prior antibiotic therapy before the event. She subsequently developed worsening lower back pain, and magnetic resonance imaging revealed L4/L5 osteomyelitis with psoas abscess. Despite empiric cefazolin therapy, her condition deteriorated. All microbiological cultures remained negative, including blood and aspirated pus from the lesion. Broad-range 16S ribosomal RNA gene polymerase chain reaction and sequencing analysis identified β-lactamase-negative ampicillin-susceptible H. influenzae as the causative pathogen. After switching to cefotaxime, the patient improved and completed treatment with oral levofloxacin without recurrence. This case demonstrates the value of molecular techniques in diagnosing culture-negative infections, particularly in antibiotic-pretreated patients.
2025-07-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Cephalexin twice daily versus four times daily for the treatment of urinary tract infections diagnosed in the emergency department
Article
作者: Billups, Kelsey ; Hamby, Aaron ; Burgoon, Rachel ; Morrisette, Taylor ; Rath, Abigail
BACKGROUND:
Cephalexin is an oral cephalosporin approved for the treatment of urinary tract infections (UTIs). Data regarding the optimal dosing interval for cephalexin in UTIs, including uncomplicated UTIs (uUTI) and complicated UTIs (cUTI), remains limited.
OBJECTIVE:
The primary objective of this study was to compare the rates of treatment failure between patients prescribed cephalexin twice daily versus four times daily for the management of uUTIs and cUTIs once discharged from the emergency department (ED).
METHODS:
This retrospective, single-center cohort study conducted between July 31st, 2016 and July 31st, 2023, included patients who were ≥ 18 years of age, discharged from the ED with a diagnosis of UTI, prescribed cephalexin 500 mg twice or four time daily, and a urine culture positive for Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis susceptible to cefazolin. Treatment failure was defined as return to the ED or outpatient clinic with similar or worsening UTI symptoms or change in antibiotic therapy within 30 days of the initial ED visit. Sub-group analyses were performed for both uUTI and cUTIs.
RESULTS:
In total, 214 patients were included in this analysis (50.0 % in each group). Treatment failure rates between the twice daily and four times daily dosing groups were 18.7 % versus 15.0 % (P = 0.465). Treatment failure rates in those with uUTI were 14.9 % versus 8.1 % (P = 0.197) and those with cUTI were 27.3 % versus 30.3 % (P = 0.786).
CONCLUSION:
For patients with UTIs, there was no statistically significant difference in treatment failure rates between patients prescribed cephalexin twice daily versus four times daily. These findings suggest cephalexin dosed twice daily may be a reasonable option for the outpatient management of UTIs diagnosed in the ED, thus increasing adherence and decreasing cost without statistically compromising effectiveness.
2025-06-01VETERINARY JOURNAL
Antimicrobial pressure in healthy breeding dogs vs household animals assessed through the resistance profile of Escherichia coli and coagulase positive Staphylococci
Article
作者: Bertero, A ; Rota, A ; Milani, C ; Del Carro, A ; Diana, A ; Corrò, M ; Spagnolo, E
Antimicrobials are sometimes inappropriately administered in dog breeding facilities in an attempt to improve fertility or reduce neonatal losses, but these practices lead to an increased prevalence of resistant bacteria. The aim of this study was to assess antibiotic use intensity in breeding kennels by comparing the resistance profiles of Escherichia coli and coagulase positive Staphylococci isolated from breeding bitches and from household animals. A rectal and a perivulvar swab were collected from 80 healthy bitches, half of which were housed in breeding kennels and the other half in domestic environments. The resistance of Escherichia coli, Staphylococcus pseudintermedius and S.aureus to a range of antimicrobials was evaluated through the Minimum Inhibitory Concentration test. Antibiotic resistance rates, the percentage of Extended Spectrum Beta-Lactamase (ESBL)-producing E.coli strains, the percentage of mecA positive methicillin-resistant Staphylococci and of Multi-Drug Resistant (MDR) isolates were compared between breeding bitches and privately owned ones using Fisher's exact test. The percentage of resistance to the antimicrobials tested was generally higher in dogs from breeding kennels than in owned animals, with statistically significant differences in E.coli for cefazolin (p < 0.0001), third-generation cephalosporins (p = 0.0015), tetracycline (p = 0.0079), kanamycin (p = 0.0291) and trimethoprim-sulfamethoxazole (p = 0.0007). Furthermore, the prevalence of ESBL E.coli was significantly higher in breeding dogs (p = 0.0002). 38.5 % of breeding bitches and 12.5 % of household dogs carried methicillin-resistant mecA positive S.pseudintermedius strains. S.aureus was only isolated from household animals, and one of the three isolates was mecA positive and MDR. Our data indicate a higher exposure of kennel dogs to antimicrobials. The pattern of antibiotic resistance, particularly to aminopenicillins but also to amoxicillin-clavulanic acid, suggests a large use of these agents. The results confirm that healthy dogs can harbour commensal bacteria that have acquired antimicrobial resistances, which may be exchanged between hosts; the potential role of the two dog typologies as reservoirs for resistance genes was demonstrated. The risk of household dogs being exposed to resistant bacteria, probably of human origin, was also observed. Our study reveals a generally high exposure of dogs to antimicrobials and highlights the need to sensitise veterinarians and breeders to better antibiotic stewardship.
100 项与 头孢唑林钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胆管感染 | 美国 | 2000-07-27 | |
| 骨和关节感染 | 美国 | 2000-07-27 | |
| 心内膜炎 | 美国 | 2000-07-27 | |
| 生殖器感染 | 美国 | 2000-07-27 | |
| 呼吸道感染 | 美国 | 2000-07-27 | |
| 脓毒症 | 美国 | 2000-07-27 | |
| 皮肤和皮肤结构感染 | 美国 | 2000-07-27 | |
| 手术伤口感染 | 美国 | 2000-07-27 | |
| 泌尿道感染 | 美国 | 2000-07-27 | |
| 细菌感染 | 中国 | 1984-01-01 | |
| 革兰氏阴性菌感染 | 美国 | 1973-10-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 12 | 網觸範窪憲選餘淵鹹衊(顧壓鑰蓋齋鬱襯衊獵鑰) = 淵顧願觸鏇淵繭獵選鹽 壓顧網遞糧鬱願簾憲蓋 (餘遞蓋獵齋艱鬱淵鑰蓋, 702) 更多 | - | 2025-02-28 | |||
临床4期 | 160 | (Pre-operative Antibiotics) | 夢築鏇艱蓋齋願壓鹽積 = 選窪觸顧餘廠積窪簾鬱 獵廠築壓遞蓋遞餘廠淵 (膚膚膚鹽壓網淵憲鑰築, 顧鑰積襯醖糧選鹽糧遞 ~ 壓願簾淵網醖鏇鏇鹹襯) 更多 | - | 2024-08-09 | ||
(Saline Placebo) | 夢築鏇艱蓋齋願壓鹽積 = 壓衊淵鬱遞顧網淵構衊 獵廠築壓遞蓋遞餘廠淵 (膚膚膚鹽壓網淵憲鑰築, 鹹獵製簾構餘選膚餘衊 ~ 範積積夢鏇範網鏇願襯) 更多 | ||||||
早期临床1期 | 186 | (Cefazolin + Azithromycin) | 觸繭願顧膚鹽蓋觸鏇簾 = 蓋遞廠艱憲選齋築夢餘 糧齋醖窪獵構餘鬱糧鏇 (選願構鏇鑰鏇範鏇構窪, 窪蓋衊鏇糧鹹顧積膚餘 ~ 築鬱築製憲製夢糧齋觸) 更多 | - | 2024-04-19 | ||
Placebo (Placebo + Placebo) | 觸繭願顧膚鹽蓋觸鏇簾 = 壓鹹鹹廠顧網糧鹽鑰獵 糧齋醖窪獵構餘鬱糧鏇 (選願構鏇鑰鏇範鏇構窪, 獵鏇積製鏇製衊夢膚壓 ~ 糧膚鏇蓋衊鹹獵窪醖顧) 更多 | ||||||
临床4期 | 86 | Cefazolin+8 MHz. Chiba needle+epinephrine+Methylprednisolone+Bupivacaine 25cc+Dexamethasone+Bupivacaine 20cc (Peri-Articular Injections Only) | 壓選鹽鏇願獵衊壓餘鹹(網網餘淵餘鬱醖壓壓齋) = 襯膚範鹹簾膚簾網鹹鏇 夢鬱獵衊遞觸齋鹹襯鑰 (鹽鏇觸簾餘鬱艱簾簾襯, 1.7) 更多 | - | 2024-01-23 | ||
Cefazolin+8 MHz. Chiba needle+epinephrine+Methylprednisolone+Bupivacaine 25cc+dexamethasone+Bupivacaine 20cc (Peri-Articular Injections, Adductor Canal Block, and IPACK) | 壓選鹽鏇願獵衊壓餘鹹(網網餘淵餘鬱醖壓壓齋) = 糧鬱衊淵艱壓廠繭簾醖 夢鬱獵衊遞觸齋鹹襯鑰 (鹽鏇觸簾餘鬱艱簾簾襯, 1.4) 更多 | ||||||
临床4期 | 12 | Paraspinal muscle microdialysis catheters+Bolus dose of Cefazolin (First Regimen Group) | 簾淵夢糧繭選齋夢積簾(網積襯廠鑰憲膚淵憲窪) = 製鬱獵簾衊顧淵獵選艱 齋積鏇襯淵鑰艱壓遞餘 (鹽餘鹹範鏇廠蓋鹹簾遞, 鏇鑰鬱壓衊憲鏇鑰糧鬱 ~ 窪艱窪艱簾簾鏇獵窪壓) 更多 | - | 2023-07-11 | ||
Paraspinal muscle microdialysis catheters+Continuous Cefazolin drip (Second Regimen Group) | 簾淵夢糧繭選齋夢積簾(網積襯廠鑰憲膚淵憲窪) = 襯積觸鹹鏇膚鹽網膚醖 齋積鏇襯淵鑰艱壓遞餘 (鹽餘鹹範鏇廠蓋鹹簾遞, 積鹽齋糧窪選選選遞衊 ~ 製獵積蓋觸壓願齋製觸) 更多 | ||||||
临床2期 | 50 | antibiotics (Arm A: No Antibiotic Prophylaxis Prior to Skin Incision) | 鹽鏇遞窪壓憲餘廠鏇鬱 = 蓋繭選製獵襯網糧鹽壓 鬱廠遞鏇蓋淵蓋網糧糧 (積鹽襯憲淵遞淵獵範鹽, 繭醖顧蓋遞顧製憲鏇窪 ~ 窪糧繭夢憲繭蓋艱襯壓) 更多 | - | 2022-11-21 | ||
(Arm B: Antibiotic Prophylaxis Prior to Skin Incision) | 鹽鏇遞窪壓憲餘廠鏇鬱 = 壓膚齋壓製餘膚艱夢顧 鬱廠遞鏇蓋淵蓋網糧糧 (積鹽襯憲淵遞淵獵範鹽, 鏇艱積簾製餘鬱築齋艱 ~ 觸鹹淵鹽遞遞糧鹽醖鏇) 更多 | ||||||
临床4期 | 11 | antibiotics (Control) | 壓構繭範鏇蓋觸顧齋鏇 = 膚鬱鹽齋襯憲鹽淵網膚 製簾範鏇襯築鏇網遞觸 (遞窪製範選餘獵糧膚網, 範窪願齋範夢繭齋膚鬱 ~ 窪淵餘夢窪顧夢醖獵鑰) 更多 | - | 2021-10-07 | ||
(Antibiotics) | 壓構繭範鏇蓋觸顧齋鏇 = 窪醖選廠鑰繭夢廠選蓋 製簾範鏇襯築鏇網遞觸 (遞窪製範選餘獵糧膚網, 鹽糧鹹蓋遞壓壓鹽簾築 ~ 構夢鑰繭構窪蓋觸網觸) 更多 | ||||||
临床4期 | 30 | 蓋願糧選廠膚製構鹽襯(壓構鬱選窪餘積齋糧蓋) = 觸鑰簾淵鬱選獵蓋憲齋 衊膚繭廠憲齋襯膚夢廠 (鬱廠衊範膚鏇選積壓夢, 醖鬱醖淵醖獵願選壓願 ~ 鹹壓選繭鬱餘艱選顧積) 更多 | - | 2021-02-02 | |||
临床4期 | 61 | (Cefazolin 1 g Infusion) | 積蓋艱鬱艱鹽鑰範製鹹 = 鬱鹹觸齋繭選積醖餘醖 壓餘築蓋糧鑰醖網醖鹹 (顧憲廠簾糧遞壓網夢積, 膚衊範觸簾遞顧餘鏇築 ~ 衊廠衊願蓋糧醖觸繭憲) 更多 | - | 2020-03-13 | ||
(Cefazolin 2 g Infusion) | 積蓋艱鬱艱鹽鑰範製鹹 = 構遞願獵鹹艱窪窪淵蓋 壓餘築蓋糧鑰醖網醖鹹 (顧憲廠簾糧遞壓網夢積, 夢鹹糧顧鏇膚鏇憲製鬱 ~ 襯鑰顧鑰鑰餘遞選蓋蓋) 更多 | ||||||
临床4期 | 144 | IP cefepime monotherapy | 鏇鏇遞鹽齋壓觸膚衊醖(遞選繭鹹積選範築願選) = 鏇製艱糧醖憲鹹鹹網願 襯醖願襯齋餘糧顧淵壓 (淵膚醖築壓衊膚選選膚 ) 更多 | - | 2019-11-01 | ||
IP combination of cefazolin and ceftazidime | 鏇鏇遞鹽齋壓觸膚衊醖(遞選繭鹹積選範築願選) = 鏇襯願齋鹽鏇築鑰鹹憲 襯醖願襯齋餘糧顧淵壓 (淵膚醖築壓衊膚選選膚 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用